zithromax and Boutonneuse-Fever

Till now there is not a gold standard therapy for Mediterranean spotted fever (MSF) in children. Standard treatment for MSF is the administration of tetracycline or chloramphenicol, however both these drugs can cause significant adverse effects in children (tetracyclines can cause staining of teeth, chloramphenicol severe hematological adverse events such as aplastic anemia, gray baby syndrome and hemolytic anemia in patients with the Mediterranean form of G6PD deficiency). We conducted two randomized clinical trials; the first compared clarithromycin versus chloramphenicol: mean time to defervescence was 36.7 +/- 18.1 h in the clarithromycin group and 47.1+/- 21.9 h in the chloramphenicol group (P= 0.047). The second trial compared clarithromycin versus azithromycin and did not show any statistically significant difference: mean time to defervescence was 46.2 +/- 36.4 h in the clarithromycin group and 39.3 +/- 31.3 h in the azithromycin group (P= 0.34). On the basis of these studies we think that clarithromycin and azithromycin could constitute an acceptable alternative to chloramphenicol and to tetracyclines for the treatment of MSF in children

Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Chloramphenicol; Clarithromycin; Female; Humans; Infant; Italy; Macrolides; Male; Randomized Controlled Trials as Topic; Sicily; Tetracyclines; Treatment Outcome

A randomized clinical trial was undertaken to compare clinical and serologic parameters of the efficacy of one-dose azithromycin in the prophylaxis of Mediterranean spotted fever (MSF) in 122 persons with a tick bite history. Antibodies to Rickettsia conorii (R. conorii) were detected by indirect immunofluorescence (IFA) assay in 55 (45.1%) of 122 subjects. Positive result was obtained in 19 (31.1%) of 61 subjects with azithromycin prophylaxis and in 36 (59.0%) of 61 subjects without prophylaxis. Clinical signs and symptoms of MSF were recorded in 6 (9.8%) and asymptomatic infection in 30 (49.2%) of 61 subjects without prophylaxis. In subjects with prophylaxis, clinical signs of the disease were not recorded at all, whereas asymptomatic infection was detected in 19 (31.1%) of 61 subjects. Based on the results obtained in our study, we assume that a single dose of azithromycin is promising in MSF prevention.

Topics: Adult; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antibodies, Bacterial; Azithromycin; Bites and Stings; Boutonneuse Fever; Child; Humans; Rickettsia conorii; Ticks

Till now there is not a gold standard therapy for Mediterranean spotted fever (MSF) in children. Standard treatment for MSF is the administration of tetracycline or chloramphenicol, however both these drugs can cause significant adverse effects in children (tetracyclines can cause staining of teeth, chloramphenicol severe hematological adverse events such as aplastic anemia, gray baby syndrome and hemolytic anemia in patients with the Mediterranean form of G6PD deficiency). We conducted two randomized clinical trials; the first compared clarithromycin versus chloramphenicol: mean time to defervescence was 36.7 +/- 18.1 h in the clarithromycin group and 47.1+/- 21.9 h in the chloramphenicol group (P= 0.047). The second trial compared clarithromycin versus azithromycin and did not show any statistically significant difference: mean time to defervescence was 46.2 +/- 36.4 h in the clarithromycin group and 39.3 +/- 31.3 h in the azithromycin group (P= 0.34). On the basis of these studies we think that clarithromycin and azithromycin could constitute an acceptable alternative to chloramphenicol and to tetracyclines for the treatment of MSF in children

Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Chloramphenicol; Clarithromycin; Female; Humans; Infant; Italy; Macrolides; Male; Randomized Controlled Trials as Topic; Sicily; Tetracyclines; Treatment Outcome

We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin (15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days) in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2 drugs. The mean time to defervescence (+/- standard deviation) was 46.2+/-36.4 h in the clarithromycin group and 39.3+/-31.3 h in the azithromycin group. These differences were not statistically significant and both drugs were equally well-tolerated. Clarithromycin and azithromycin could be acceptable therapeutic alternatives to chloramphenicol and tetracyclines for children aged < or =8 years with Mediterranean spotted fever. Azithromycin, because it has a long half-life, offers the advantages of administration in a single daily dose and a shorter duration of therapy, which could increase compliance in children.

Topics: Adolescent; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Female; Humans; Infant; Male; Rickettsia conorii; Treatment Outcome

Topics: Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Child, Preschool; Doxycycline; Female; Humans; Male

We report the case of a 3-year-old patient with Mediterranean spotted fever (MSF). The patient was infected through a tick bite in the forests surrounding Paris. Treatment with azithromycin was started with good results. MSF is not exceptional and should be considered in patients with fever, rash, and eruptions even outside the usual infested areas.

Topics: Animals; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child, Preschool; Exanthema; Fever; Humans; Male; Paris; Rickettsia conorii; Tick Bites; Treatment Outcome

DEBONEL/TIBOLA is a tick-borne acute/sub-acute infection transmitted in our environment by Dermacentor marginatus and mainly caused by Rickettsia slovaca. The aim of our study was to know the effect of starting early treatment in the course of the DEBONEL/TIBOLA.

Topics: Adult; Animals; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Dermacentor; Doxycycline; Humans; Lymphatic Diseases; Tick-Borne Diseases

Antibodies to Rickettsia conorii were detected by the indirect immunofluorescence (IFA) assay in 64 (51.6%) out of 124 examinees living in North Dalmatia (Croatia) who had a history of recent tick bites during 1994 and 1995. Positive titers of IFA antibodies to R. conorii were detected in 12 (31.5%) out of 38 examinees with carried out prophylaxis by azithromycin. The usual clinical signs of Mediterranean spotted fever were registered in 22 (25.6%) and asymptomatic infection in 30 (34.8%) out of 86 examinees without prophylaxis. Clinical signs of the disease were not registered in examinees with prophylaxis.

Topics: Adult; Anti-Bacterial Agents; Azithromycin; Boutonneuse Fever; Child; Humans